Co-Authors
This is a "connection" page, showing publications co-authored by CARL ALLEN and OLIVE ECKSTEIN.
Connection Strength
3.161
-
Histiocytic Disorders of Childhood. Pediatr Rev. 2022 Oct 01; 43(10):561-571.
Score: 0.898
-
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Blood Adv. 2024 Mar 01.
Score: 0.248
-
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2235-2245.
Score: 0.217
-
IFN-? signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS. Blood Adv. 2021 09 14; 5(17):3457-3467.
Score: 0.209
-
Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma. Cancers (Basel). 2020 Dec 02; 12(12).
Score: 0.198
-
Management of severe pulmonary Langerhans cell histiocytosis in children. Pediatr Pulmonol. 2020 08; 55(8):2074-2081.
Score: 0.191
-
Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. Blood Adv. 2020 01 14; 4(1):87-99.
Score: 0.186
-
Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019 04 11; 133(15):1691-1694.
Score: 0.174
-
CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018 06 15; 124(12):2607-2620.
Score: 0.165
-
A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility. Blood. 2017 11 16; 130(20):2229-2232.
Score: 0.158
-
Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 Mar 19.
Score: 0.062
-
Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 Mar 19.
Score: 0.062
-
Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. J Allergy Clin Immunol. 2022 02; 149(2):758-766.
Score: 0.052
-
Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood. 2021 04 01; 137(13):1777-1791.
Score: 0.051
-
Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH. Br J Haematol. 2020 03; 188(6):e84-e87.
Score: 0.047
-
Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019 11; 66(11):e27929.
Score: 0.045
-
Thalidomide, A Rational Agent for Treatment of Multicentric Reticulohistiocytosis. Dermatol Case Rep. 2019; 4(1).
Score: 0.044
-
Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018 07 05; 132(1):89-100.
Score: 0.041
-
Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. Oncotarget. 2017 Jul 11; 8(28):46065-46070.
Score: 0.039
-
Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: A population-based case-control study. Pediatr Blood Cancer. 2017 05; 64(5).
Score: 0.037
-
Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016 11 17; 128(20):2462-2465.
Score: 0.037